Mitral regurgitation (MR) is a common cardiac valve lesion, developing from primary lesions of the mitral valve or secondary to cardiomyopathies. Moderate or higher severity of mitral regurgitation imposes significant volume overload on the left ventricle, causing permanent structural and functional deterioration of the myocardium and heart failure. Since correction of mitral regurgitation can provide symptomatic relief and halt progressive cardiac dysfunction, transcatheter mitral valve repair technologies are emerging as alternative therapies.
Enlight medical is developing transcatheter mitral valve repair and replacement devices, and its repair device NovoClaspTM is now in the pivotal clinical study in China.
@Copyright 2020-2022 Enlight Medical Limited All rights reserved 滬ICP備20012889號-2
